NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Cancer Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Cancer Vaccines



"Induction of Tumour Rejection By B7.1 and IL-2 Expressing Tumour Cells."



November 24th, 1997

According to an abstract submitted by the author to the 3rd European Conference on Gene Therapy of Cancer, held September 11-13, 1997, in Berlin, Germany, "Vaccination with genetically modified tumour cells expressing both IL-2 and the immune co-stimulatory molecule B7.1 can induce immune-mediated rejection of the modified cells, in murine models. More importantly, distant subcutaneous vaccination with lethally irradiated B7.1/IL-2 expressing cells can induce the rejection of established tumours. Efficient induction of tumour rejection depends on the presence of IL-2 at the site of vaccination and cannot be substituted by systemic administration of IL-2. The vaccination induced...


Source: Cancer Weekly (1997-11-24)

NewsRx Passes
Advertisement
More Articles

------------------------
Security by Verisign PR Login